

Clinical Policy: Ledipasvir/Sofosbuvir (Harvoni)

Reference Number: PA.CP.PHAR.279

Effective Date: 08/17

Last Review Date: 07/17/19

[Revision Log](#)

Description

Ledipasvir/sofosbuvir (Harvoni[®]) is a fixed-dose combination of ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor.

FDA-Approved Indication

Harvoni is indicated for the treatment of chronic hepatitis C virus (HCV) in:

- Adults with genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis;
- Adults with genotype 1 infection with decompensated cirrhosis, in combination with ribavirin;
- Adults with genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, in combination with ribavirin;
- Pediatric patients 12 years of age and older or weighing at least 35 kg with genotype 1, 4, 5, or 6 without cirrhosis or with compensated cirrhosis.

Policy/Criteria

It is the policy of Pennsylvania Health and Wellness[®] that Harvoni is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

*** Provider must submit documentation (including office chart notes and lab results) supporting that member has met all approval criteria ***

A. Chronic Hepatitis C Infection (must meet all):

1. Diagnosis of chronic hepatitis C virus (HCV) infection with documented genotyping;
2. If actively abusing alcohol or IV drugs, or has a history of abuse, has documentation of prescriber counseling regarding the risks of alcohol or IV drug abuse and an offer of a referral for substance use disorder treatment;
3. Has a Metavir fibrosis score documented by a recent noninvasive test such as a blood test or imaging, a Fibroscan, or findings on physical examination;
4. Has documented completion of the following (a or b, c, d, and e):
 - a. Hepatitis B immunization series; or
 - b. Hepatitis B screening (sAb/sAg and cAb);
 - c. If positive for hepatitis B sAg, quantitative HBV DNA results;
 - d. If there is detectable HBV DNA, a treatment plan for hepatitis B consistent with AASLD recommendations; and
 - e. If negative for hepatitis B sAb, a hepatitis B immunization plan or counseling to receive the hepatitis B immunization series;
5. Has a documented HIV screening (HIV Ag/Ab) and if confirmed positive by HIV-1/HIV-2 differentiation immunoassay meets the following (a or b):
 - a. Is being treated for HIV or is not being treated for HIV; or
 - b. The medical record documents the rationale for not being treated;

6. Has documentation of AASLD-recommended resistance- associated substitution (RAS) testing and is prescribed a drug regimen in accordance with AASLD guidance;
7. If genotype 1a, or had a previous treatment failure with a direct-acting antiretroviral (DAA) regimen, is prescribed an AASLD recommended drug regimen based on the documented results of a NS5A RAS screening;
8. Does not have a life expectancy of less than 12 months due to non-liver-related comorbid conditions;
9. Has a documented quantitative HCV RNA at baseline that was tested within the past 3 months;
10. Has corrected or addressed the causes of non-adherence to a previously prescribed Hepatitis C treatment regimen if the member has a history of failed treatment due to non-adherence;
11. Had all potential drug interactions addressed by the prescriber;
12. Prescribed regimen is consistent with an FDA or AASLD-IDSA recommended regimen (*see Section V Dosage and Administration for reference*);
 - a. If a lower cost alternative regimen carries an equal or higher AASLD-IDSA rating, a clinical contraindication or intolerance must be present for the alternative regimen prior to the approval of a Harvoni-based regimen;
13. If prescribed with ribavirin, no changes will be required of therapy;
14. Has a documented commitment to adherence with the planned course of treatment and appropriate monitoring;

Approval duration: up to 24 weeks (**Approved duration should be consistent with a regimen in Section V Dosage and Administration*)

- B. Other diagnoses/indications:** Refer to PA.CP.PMN.53 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

II. Continued Approval

**** Provider must submit documentation (including office chart notes and lab results) supporting that member has met all approval criteria ****

A. Chronic Hepatitis C Infection (must meet all):

1. Currently receiving medication via Pennsylvania Health and Wellness benefit or member has previously met all initial approval criteria or the Continuity of Care policy (PA.LTSS.PHAR.01) applies;
2. Dose does not exceed ledipasvir/sofosbuvir 90 mg/400 mg per day (1 tablet/day).

Approval duration: up to a total of 24 weeks*
(**Approved duration should be consistent with a regimen in Section V Dosage and Administration*)

B. Other diagnoses/indications

1. Refer to PA.CP.PMN.53 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – PA.CP.PMN.53 or evidence of coverage documents.

IV. Appendices

Appendix A: Abbreviation Key

ALT: alanine aminotransferase	HCC: hepatocellular carcinoma
APRI: AST to platelet ratio	HCV: hepatitis C virus
AASLD: American Association for the Study of Liver Diseases	IDSA: Infectious Diseases Society of America
CHC: chronic hepatitis C	MRE: magnetic resonance elastography
FDA: Food and Drug Administration	NS3/4A, NS5A/B: nonstructural protein
CTP: Child Turcotte Pugh	Peg-IFN: pegylated interferon
FIB-4: Fibrosis-4 index	PI: protease inhibitor
HBeAg: hepatitis B virus envelope antigen	RBV: ribavirin
HBV: hepatitis B virus	RNA: ribonucleic acid

Appendix B: General Information

- Hepatitis B Reactivation is a Black Box Warning for all direct-acting antiviral drugs for the treatment of HCV. The provider must provide either:
 - Documentation of absence of concurrent HBV infection as evidenced by laboratory values showing absence of hepatitis B virus envelope antigen (HBeAg) and HBV DNA;
 - Documentation that HBV co-infected patient may not be candidates for therapy as evidenced by one of the following:
 - Absence of HBeAg, HBV DNA less than 2,000 international units/mL, and alanine aminotransferase (ALT) level within 1 to 2 times the upper limit of normal;
 - HBeAg-positive and HBV DNA greater than 1,000,000 international units/mL and ALT level within 1 to 2 times the upper limit of normal;
 - Documentation that concurrent HBV infection is being treated (e.g., tenofovir alafenamide, adefovir, entecavir), unless contraindicated or clinically significant adverse effects are experienced.
- The 2016 AASLD/IDSA treatment guideline for HBV consider ALT levels <30 U/L for men and <19 U/L for women as upper limits of normal.
- The 2016 AASLD/IDSA treatment guideline for HBV recommend adults with compensated cirrhosis, even with low levels of viremia (<2,000 IU/mL) be treated with antiviral therapy to reduce the risk of decompensation, regardless of ALT level. The recommendation extends to adults with decompensated cirrhosis be treated with antiviral therapy indefinitely regardless of HBV DNA level, HBeAg status, or ALT level to decrease the risk of worsening liver-related complications.

Appendix C: Direct-Acting Antivirals for Treatment of HCV Infection

Brand Name	Drug Class				
	NS5A Inhibitor	Nucleotide Analog NS5B Polymerase Inhibitor	Non-Nucleoside NS5B Polymerase Inhibitor	NS3/4A Protease Inhibitor (PI)**	CYP3A Inhibitor
Daklinza	Daclatasvir				
Epclusa*	Velpatasvir	Sofosbuvir			
Harvoni*	Ledipasvir	Sofosbuvir			
Olysio				Simeprevir	
Sovaldi		Sofosbuvir			
Technivie*	Ombitasvir			Paritaprevir	Ritonavir
Viekira XR/PAK*	Ombitasvir		Dasabuvir	Paritaprevir	Ritonavir
Zepatier*	Elbasvir			Grazoprevir	

*Combination drugs

**Additional PIs no longer recommended: Victrelis (boceprevir), Incivek (telaprevir)

V. Dosage and Administration

- a. **AASLD/IDSA treatment guidelines for chronic hepatitis C infection are updated at irregular intervals; refer to the most updated AASLD/IDSA guideline for most accurate treatment regimen.*

VI. Product Availability

Tablet: 400 mg sofosbuvir with 90 mg ledipasvir

Updated policy to incorporate DUR Memo dated 12.10.18.	1.7.2019	
3Q 2019 annual review: No changes per Statewide PDL implementation 01-01-2020	07/17/19	

References

1. Harvoni Prescribing Information. Foster City, CA: Gilead Sciences, Inc.; April 2017. Available at http://www.gilead.com/~media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf. Accessed May 2017
2. American Association for the Study of Liver Diseases/ Infectious Disease Society of America (AASLD-IDSA). Recommendations for testing, managing, and treating hepatitis C. <http://www.hcvguidelines.org>. Accessed May, 2017.
3. Bonder A, Afdhal N. Utilization of FibroScan in clinical practice. *Curr Gastroenterol Rep*. 2014; 16(372): 1-7. DOI 10.1007/s11894-014-0372-6.
4. Halfon P, Bourliere M, Deydier R, et al. Independent prospective multicenter validation of biochemical markers (Fibrotest–Actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: The Fibropaca study. *Am J Gastroenterol*. 2006; 101: 547-555. DOI: 10.1111/j.1572-0241.2006.04111.x
5. Hepatitis C Virus (HCV) FibroSure. Laboratory Corporation of America Holdings and Lexi-Comp, Inc. Available at <https://www.labcorp.com>. 2016. Accessed July 15, 2016.
6. Hepatitis C Virus (HCV) FibroTest-ActiTest Panel. Nichols Institute/Quest Diagnostics. Available at http://education.questdiagnostics.com/physician_landing_page. 2016. Accessed July 15, 2016.
7. Hepatitis C Virus (HCV) FIBROSpect II. Prometheus Therapeutics and Diagnostics. Available at http://www.prometheuslabs.com/Resources/Fibrospect/Fibrospect_II_Product_Detail_Sheet_FIB16005_04-16.pdf. April 2016. Accessed July 15, 2016.
8. Hsieh YY, Tung SY, Lee K, et al. Routine blood tests to predict liver fibrosis in chronic hepatitis C. *World J Gastroenterol*. February 28, 2012; 18(8): 746-53. doi: 10.3748/wjg.v18.i8.746.
9. Bruix J and Sherman M. Management of hepatocellular carcinoma: An update. AASLD Practice Guideline. *Hepatology*. 2011; 53(3): 1020-22.
10. Terrault NA, Bzowej NH, Chang KM, et al. AASLD Guidelines for Treatment of Chronic Hepatitis B. *Hepatology* 2016; 62(1): 261-283.